

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (original) A method for detecting teneurin signalling, which method comprises:
 - a) determining the presence of a cleaved teneurin product associated with teneurin signalling, wherein said cleaved teneurin product comprises at least a portion of the cytoplasmic domain of teneurin and targets to the cell nucleus; and
 - b) correlating the presence and/or amount of said cleaved teneurin product with teneurin signalling.
2. (original) A method as claimed in claim 1, wherein said teneurin is teneurin-1, teneurin-2, teneurin-3 or teneurin-4.
3. (currently amended) A method as claimed in ~~any one of the preceding claims~~ wherein the cleaved teneurin product is formed in turnout cells.
4. (currently amended) A method as claimed in claim 1 ~~or 2~~, wherein the cleaved teneurin product is formed in neurons.
5. (currently amended) A method as claimed in ~~any one of the preceding claims~~ further comprising providing a teneurin or a fragment thereof comprising at least a portion of the N terminal domain of teneurin and at least a portion of the C-terminal domain of teneurin, and a cellular component that cleaves teneurin.
6. (original) A method as claimed in claim 5, wherein the teneurin is recombinant.
7. (currently amended) A method as claimed in ~~any one of the preceding claims~~ 6 wherein the cleaved teneurin product comprises a tag or label.
8. (original) A method as claimed in claim 7, wherein said determining step (b) comprises detecting said tag or label photometrically.
9. (currently amended) A method as claimed in claim 7 ~~or 8~~, wherein said tag is selected from the group consisting of GFP, YFP, hemagglutinin, (Histidine)₇, a DNA binding domain.

- 10.(original) A method as claimed in claim 9 wherein said determining step (b) comprises allowing said DNA binding domain to bind to a nucleic acid comprising regulatory sequences operably linked to a reporter gene and detecting activity of said reporter gene.
11. (original) A method as claimed in claim 10 wherein said DNA binding domain comprises a GAL4 DNA binding domain.
12. (currently amended) A method as claimed in claim 9, ~~10 or 11~~ wherein said tag is a DNA binding domain and further comprises an NF κ B domain.
13. (currently amended) A method as claimed in ~~any one of the preceding claims~~ wherein said determining step comprises determining the amount of said cleaved tenascin product.
14. (currently amended) A method as claimed in ~~any one of the preceding claims~~ wherein the cleaved teneurin product regulates expression or activity of a cellular target.
15. (original) A method as claimed in claim 14 further comprising detecting expression or activity of said cellular target.
16. (original) A method as claimed in claim 15 wherein said cellular target is PAL.
- 17.(original) A method as claimed in claim 15 wherein said cellular target is Zic.
18. (original) A method as claimed in claim 15 wherein said cellular target is ponsin.
- 19.(original) A method as claimed in claim 1, wherein the presence and/or amount of the cleaved teneurin product is correlated to a particular disease or condition.
20. (original) A method as claimed in claim 19, wherein said disease or condition is dependent on cell proliferation and/or neuronal differentiation.
21. (original) Use of a detectable cleaved teneurin product associated with teneurin signalling in a method of diagnosis of a neuropathology or cell pathology affected by teneurin signalling.
22. (original) A method for assessing the ability of an agent to modulate teneurin signalling, comprising the steps of:
 - (a) contacting teneurin with at least one agent;

- (b) detecting cleavage of said teneurin by a cellular component associated with teneurin signalling in the presence of said agent; and
 - (c) correlating a difference in cleavage of said teneurin relative to when said agent is absent with an indication of the presence of an agent effective in modulating teneurin signalling.
23. (original) A method as claimed in claim 22 wherein step (a) is performed by perfusing a cell expressing recombinant teneurin with the agent.
24. (original) A method for assessing the ability of an agent to modulate teneurin-mediated signalling, comprising the steps of:
- (a) exposing a cell to an agent;
 - (b) detecting expression or activity of a gene regulated by teneurin in said cell; and
 - (c) correlating a change in expression or activity of said gene with the presence of a modulator of teneurin signalling.
25. (currently amended) The use of an agent detected by a method of ~~any one of claims 22 to 24~~ for the manufacture of a medicament for the treatment or prophylactic treatment of a neuropathological condition.
26. (currently amended) The use of an agent detected by a method of ~~any one of claims 22 to 24~~ for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer.
27. (original) The use of a cleaved teneurin product associated with teneurin signalling, wherein said cleaved teneurin product comprises at least a portion of the cytoplasmic domain of teneurin and targets to the cell nucleus; for the manufacture of a medicament for the treatment or prophylactic treatment of tumourigenesis or cancer.
28. (original) The use of a cleaved teneurin product associated with teneurin signalling, wherein said cleaved teneurin product comprises at least a portion of the cytoplasmic domain of teneurin and targets to the cell nucleus; for the manufacture of a medicament for the treatment or prophylactic treatment of a neuropathological condition.
29. (currently amended) A method of treating an individual in need of treatment or prophylactic treatment of tumorogenesis, cancer or a neuropathological condition, said method comprising administering an effective amount of an agent identified by ~~any one of claims 22 to 24~~ sufficient to ameliorate the symptoms of said individual.

30. (original) A method of treating an individual in need of treatment or prophylactic treatment of tumorigenesis, cancer or a neuropathological condition, said method comprising administering an effective amount of a cleaved teneurin product comprising at least a portion of the cytoplasmic domain of teneurin, which targets to the cell nucleus, sufficient to ameliorate the symptoms of said individual.
31. (original) A composition comprising a cleaved teneurin product and a cellular target of the cleaved teneurin product.
32. (original) The composition of claim 31, wherein said cleaved teneurin product comprises at least a portion of the cytoplasmic domain of teneurin and targets to the cell nucleus.
33. (currently amended) A composition as claimed in claim 31 ~~or 32~~ wherein said cellular target is PML.
34. (currently amended) A composition as claimed in claim 31 ~~or 32~~ wherein said cellular target is Zic.
35. (currently amended) A composition as claimed in claim 31 ~~or 32~~ wherein said cellular target is ponsin.
36. (currently amended) A composition as claimed in claim 31 ~~or 32~~ wherein said cellular target is myc.
37. (currently amended) A composition as claimed in claim 31 ~~or 32~~ wherein said cellular target is p53.
38. (original) A kit comprising a teneurin and a protease.